Research Use Only — Confirm to Continue

OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.

By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.

Research Use Only · Dosing data compiled from published literature · Not for human or veterinary use
OptimalDosages

BPC-157 Dosage & Reconstitution

Body Protection Compound 157, PL 14736. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.

1Set Up Your Mix

1 mg/mL · 1000 mcg/mL
All answers assume a standard 1 mL U-100 syringe, where 1 unit = 0.01 mL. That is the usual insulin syringe and the one every number here is based on.

Your Answer — BPC-157Your Answer

—
25Draw To This Line
0.25That's This Many mL
20Doses In The Vial
0102030405060708090100 U-100 syringe · 1 mL · 100 units draw to 25
5 mg ÷ 5 mL = 1 mg/mL  →  250 mcg ÷ 1 mg/mL = 0.25 mL  →  × 100 = 25 units—
Looks good. Draw to 25 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 20 doses.

2Week-By-Week Plan — BPC-157

Start low, work up
WhenDoseHow OftenHow Many mLDraw ToNumber Of DosesPeptide Used
Low reported 200 mcg 1× daily 0.2 mL 20 u 25 doses
Commonly reported 250 mcg 1–2× daily 0.25 mL 25 u 20 doses
Upper reported 500 mcg 1–2× daily 0.5 mL 50 u 10 doses
Research study dose10 mcg/kgdaily, 7–21 d Set by body weight — can't be turned into a single amount to draw
Weeks until the top dose
4 weeks
Peptide used getting there
6.3 mg
Vials you'll need
2 × 5 mg
Once you're at the top dose
14 mg / 4 wk · 2.8 vials
Where this plan came from
Built from this peptide's dose range
Where this came from: Built from the doses listed for this peptide below — start at the lowest and step up, using the studies cited on this page. Nobody publishes a week-by-week plan for this peptide, so we built one: the doses are the researched ones shown below, and we simply put them in order from lowest to highest. Treat it as a starting point, not an official schedule.

3Common Doses — BPC-157

worked out for your mix
LevelDoseHow OftenHow Many mLDraw ToDoses In Vial
Weeks 1–2 200 mcg daily 0.2 mL 20 u 14 2.8 mg
Weeks 3–4 250 mcg daily 0.25 mL 25 u 14 3.5 mg
Week 5 onward
per 4 weeks from here on		 500 mcg daily 0.5 mL 50 u 28 14 mg
Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About BPC-157About This Peptide

Tissue Repair & Recovery
Also known as
Body Protection Compound 157, PL 14736
Class
Tissue Repair & Recovery
Route
Subcutaneous
Half-life
~4 h (preclinical)
Evidence tier
Preclinical

A pentadecapeptide fragment derived from a sequence in human gastric juice. The published record is almost entirely preclinical research on tendon, ligament, muscle and gastrointestinal healing. There is no completed, published human efficacy trial, and reported doses are extrapolations from weight-based research figures rather than clinically established ranges.

Buy BPC-157this peptide

Opens optimal-pep.com in a new tab

Where These Numbers Come From

Preclinical — Preclinical and in-vitro data only — no human dosing trials
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract Sikiric P, et al. Current Pharmaceutical Design, 2011
The core review from the group responsible for most BPC-157 literature; establishes the research dose ranges everything else cites.
Find on PubMed ↗
Pentadecapeptide BPC 157 and the central nervous system Sikiric P, et al. Neural Regeneration Research, 2022
Extends the model beyond soft tissue; useful for judging how broad and how thinly evidenced the claimed mechanism is.
Find on PubMed ↗
BPC 157 and standard angiogenic growth factors in tendon healing Chang CH, et al. Journal of Applied Physiology, 2011
Achilles tendon model; one of the more frequently cited tendon-specific results.
Find on PubMed ↗
Safety and pharmacokinetics of BPC 157 — regulatory status review FDA 503A Bulks List review record, 2020
Documents the regulatory finding that human safety and PK data are insufficient; important counterweight to the preclinical enthusiasm.
Find on PubMed ↗

Newest Studies — —

—
Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

More peptides

Browse the full catalogue, or jump to a neighbouring compound.

Retatrutide / Cagrilintide Blend

Equal parts of a triple incretin agonist and an amylin analogue — 5 mg of each in a 10 mg vial, once weekly. The thing to understa…

TB-500

A synthetic fragment of thymosin beta-4, the actin-sequestering protein. Full-length Tβ4 reached human trials for dry eye and card…

All 71 peptides

Every compound compared in one table: dose range, how often, half-life and evidence tier.